Researchers Study Nasal Administration of Bionor Pharma's Therapeutic HIV Vaccine Vacc-4x Combined With Eurocine Vaccines' Endocine(TM) in Fully Enrolled Trial; New Treatment Option Would Offer Easier Treatment Access for HIV Patients Globally
04 janv. 2012 08h00 HE
|
Bionor Pharma
OSLO, NORWAY--(Marketwire - Jan 4, 2012) -
News Summary
Bionor Pharma's Vacc-4x is an investigational therapeutic HIV vaccine that has already shown in a...
Bionor Pharma's Universal Influenza Vaccine, Vacc-Flu, Targets Regions Shared by All Influenza A Strains; Reduces Serious Flu Symptoms by 25 Percent Over Standard Flu Vaccine in Animal Study
22 nov. 2011 08h00 HE
|
Bionor Pharma
ARLINGTON, VA--(Marketwire - Nov 22, 2011) -
Summary of Findings
Bionor's Vacc-Flu could be "Universal," meaning that it could work on seasonal flu and also on...
Results From Phase IIB Placebo Controlled Study of Bionor Pharma's Vacc-4x Show Excellent Safety Profile, Statistically Significant Viral Load Reduction in Patients With HIV Who Suspend Antiretroviral Therapy
14 sept. 2011 02h30 HE
|
BionorPharma
BANGKOK, THAILAND--(Marketwire - Sep 14, 2011) - Results from the furthest advanced study of a therapeutic vaccine candidate to treat people living with HIV/AIDS were announced at a news conference...
Bionor Pharma ASA Announces Exploratory Study of Its Lead Therapeutic HIV-Vaccine Candidate Vacc-4x in Combination With Leading Cancer Drug
25 août 2011 08h00 HE
|
BionorPharma
OSLO, NORWAY--(Marketwire - Aug 25, 2011) - Bionor Pharma ASA (OSLO: BIONOR) announces plans to conduct an exploratory clinical study using Bionor Pharma's therapeutic HIV-vaccine candidate,...
Further Analysis of Vacc-4x Phase IIb Study Shows a Statistically Significant Reduction in Viral Load Over Placebo -- Previous Decision to Put Vacc-4x on Hold Has Been Reversed
18 nov. 2010 09h05 HE
|
Bionor Pharma
OSLO, NORWAY--(Marketwire - November 18, 2010) - After further analyses of the international, randomized, double-blind, placebo-controlled multi-center phase IIb study of Bionor Pharma's (OSLO:...
Henrik Lund MD Ph.D, Former Global VP in Clinical Development at Astra Zeneca, Named New CEO of Bionor Pharma ASA
30 août 2010 09h14 HE
|
BionorPharma
OSLO, NORWAY--(Marketwire - August 30, 2010) - Bionor Pharma (OSLO: BIONOR) today announced that Henrik Lund MD Ph.D, will take over the position of CEO from Trond Syvertsen effective from 1...
Two Thirds of Study Volunteers Respond to First-Ever "Re-Vaccination" of Vacc-4x, Bionor Pharma's Peptide-Based Therapeutic HIV-Vaccine
30 août 2010 09h13 HE
|
BionorPharma
OSLO, NORWAY and WASHINGTON, DC--(Marketwire - August 30, 2010) -
Study Highlights: 25 volunteers from previously conducted Phase 2a trial were "re-vaccinated" with the vaccine after 7...
Researchers Present Findings Today at the XVIII International AIDS Conference, Vienna Austria
22 juil. 2010 06h59 HE
|
BionorPharma
VIENNA, AUSTRIA--(Marketwire - July 22, 2010) - Researchers at Oslo University Hospital and Bionor Pharma's subsidiary, Bionor Immuno AS today presented results from a recently conducted...
UPDATE: NutriPharma ASA and Subsidiary Bionor Immuno AS Change Name to Bionor Pharma ASA; New Board Selected by Shareholders at Annual General Meeting
27 mai 2010 10h48 HE
|
BionorPharma
OSLO, NORWAY--(Marketwire - May 27, 2010) - Norwegian Nutri Pharma ASA (OSLO: NUT) and its subsidiary Bionor Immuno AS today announced that the parent Company Nutri Pharma ASA will now be known...
New Path to Therapeutic HIV Vaccine Discovered by Studying Immunologic Profile of Rare HIV Controllers
17 mars 2010 11h30 HE
|
Bionor Immuno
OSLO, NORWAY--(Marketwire - March 17, 2010) - Based on encouraging results from pre-clinical research, Bionor Immuno AS today announced intentions to take the therapeutic and potentially...